Literature DB >> 19460942

Evaluation of 13q14 status in patients with chronic lymphocytic leukemia using single nucleotide polymorphism-based techniques.

Katy Hanlon1, Sian Ellard, Claudius E Rudin, Susan Thorne, Teresa Davies, Lorna W Harries.   

Abstract

Deletions of chromosome 13q14 are common in chronic lymphocytic leukemia and other cancers, demonstrating the importance of this region in tumorigenesis. We report the use of two single-nucleotide polymorphism (SNP)-based techniques to determine 13q loss of heterozygosity (LOH) status in 15 patients with CLL: (i) digital SNP (dSNP), where analysis of heterozygous SNPs detects allelic imbalances, and (ii) DNA sequencing, where LOH is identified by comparison of allelic peak heights in normal and neoplastic cells. The SNP-based techniques were compared with established molecular techniques, fluorescence in situ hybridization and multiplex ligation-dependent probe amplification, to determine their utility and relative sensitivity. dSNP proved to be the most sensitive technique, identifying 13q14 LOH in 11 of 13 (85%) patients (95% CI: 55%, 98%) without the need for neoplastic cell enrichment. Three cases showed evidence of LOH by dSNP that was not apparent by other techniques. In 8 of 13 (62%) cases, partial or interstitial patterns of LOH were observed by dSNP. Our findings demonstrate that dSNP represents a useful, sensitive technique for the analysis of chromosomal aberrations that result in LOH. It may have applications for the analysis of other malignancies that are difficult to assess by conventional molecular techniques.

Entities:  

Mesh:

Year:  2009        PMID: 19460942      PMCID: PMC2710705          DOI: 10.2353/jmoldx.2009.080167

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  17 in total

1.  Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations.

Authors:  Carsten Schwaenen; Michelle Nessling; Swen Wessendorf; Tatjana Salvi; Gunnar Wrobel; Bernhard Radlwimmer; Hans A Kestler; Christian Haslinger; Stephan Stilgenbauer; Hartmut Döhner; Martin Bentz; Peter Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-16       Impact factor: 11.205

Review 2.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

3.  Counting alleles to predict recurrence of early-stage colorectal cancers.

Authors:  Wei Zhou; Steven N Goodman; Gennaro Galizia; Eva Lieto; Francesca Ferraraccio; Carlo Pignatelli; Colin A Purdie; Juan Piris; Robert Morris; David J Harrison; Philip B Paty; Al Culliford; Katharine E Romans; Elizabeth A Montgomery; Michael A Choti; Kenneth W Kinzler; Bert Vogelstein
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

4.  Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia.

Authors:  Llorenç Coll-Mulet; Antonio F Santidrián; Ana M Cosialls; Daniel Iglesias-Serret; Mercè de Frias; Javier Grau; Anna Menoyo; Eva González-Barca; Gabriel Pons; Alicia Domingo; Joan Gil
Journal:  Br J Haematol       Date:  2008-06-17       Impact factor: 6.998

5.  Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies.

Authors:  R La Starza; I Wlodarska; A Aventin; D Falzetti; B Crescenzi; M F Martelli; H Van den Berghe; C Mecucci
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

6.  Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

Authors:  T Facon; H Avet-Loiseau; G Guillerm; P Moreau; F Geneviève; M Zandecki; J L Laï; X Leleu; J P Jouet; F Bauters; J L Harousseau; R Bataille; J Y Mary
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

7.  Rituximab dose-escalation trial in chronic lymphocytic leukemia.

Authors:  S M O'Brien; H Kantarjian; D A Thomas; F J Giles; E J Freireich; J Cortes; S Lerner; M J Keating
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

8.  Counting alleles reveals a connection between chromosome 18q loss and vascular invasion.

Authors:  W Zhou; G Galizia; E Lieto; S N Goodman; K E Romans; K W Kinzler; B Vogelstein; M A Choti; E A Montgomery
Journal:  Nat Biotechnol       Date:  2001-01       Impact factor: 54.908

9.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.

Authors:  G Juliusson; D G Oscier; M Fitchett; F M Ross; G Stockdill; M J Mackie; A C Parker; G L Castoldi; A Guneo; S Knuutila; E Elonen; G Gahrton
Journal:  N Engl J Med       Date:  1990-09-13       Impact factor: 91.245

10.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.

Authors:  E Matutes; K Owusu-Ankomah; R Morilla; J Garcia Marco; A Houlihan; T H Que; D Catovsky
Journal:  Leukemia       Date:  1994-10       Impact factor: 11.528

View more
  3 in total

1.  Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology.

Authors:  Katy Hanlon; Lorna W Harries; Sian Ellard; Claudius E Rudin
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

2.  Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?

Authors:  Beyhan Durak Aras; Sevgi Isik; Hava Uskudar Teke; Abdulvahap Aslan; Filiz Yavasoglu; Zafer Gulbas; Fatih Demirkan; Hulya Ozen; Oguz Cilingir; Nur Sena Inci; Gulcin Gunden; Tuba Bulduk; Ebru Erzurumluoglu Gokalp; Sinem Kocagil; Sevilhan Artan; Olga Meltem Akay
Journal:  Mol Cytogenet       Date:  2021-01-06       Impact factor: 2.009

3.  Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K).

Authors:  Beata Grygalewicz; Renata Woroniecka; Jolanta Rygier; Klaudia Borkowska; Iwona Rzepecka; Martyna Łukasik; Agnieszka Budziłowska; Grzegorz Rymkiewicz; Katarzyna Błachnio; Beata Nowakowska; Magdalena Bartnik; Monika Gos; Barbara Pieńkowska-Grela
Journal:  Mol Cytogenet       Date:  2016-01-06       Impact factor: 2.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.